A breast cancer survivorship expert shares her top advice for counseling patients on endocrine therapy at the 5-year mark.

Panelists discuss how strategic nursing coordination and effective communication support timely and comprehensive biomarker testing for newly diagnosed NSCLC patients.

Panelists discuss how evolving clinical advances and biomarker-driven therapies have transformed treatment practices and outcomes for patients with ALK+ NSCLC.

A care model led by advanced practice nurses was feasible in providing supportive care and linking providers through post-trial care transitions.

Maria C. Velez, MD, shared that teamwork between pediatric and adult care teams can make the transition of care smoother for AYA patients.

An observational study found IHC may serve as a biomarker for early detection of TP53‐mutant MDS or AML and prediction of TP53 allelic state.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.

The addition of avutometinib to defactinib showed promising safety and efficacy for patients with low-grade serous ovarian cancer.

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.

Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, explains how a fellowship program sets the tone for how to transition nurse practitioners to oncology.

FDA accelerated approval was given to zongertinib for the treatment of patients with unresectable/metastatic nonsquamous NSCLC with HER2 TKD activating mutations.

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says Stephanie Mompoint, APRN.

This Rx Road Map outlines the most important information nurses should know when treating patients with astrocytoma or oligodendroglioma with vorasidenib.

Ronald Bleday, MD, explained that a model to reduce opioid use in patients after colorectal surgery relies on nurses familiar with the relevant surgeries.

Panelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain fog and weight gain while maintaining disease control, emphasizing the importance of multidisciplinary team support, including palliative care from diagnosis.

The FDA has granted accelerated approval to dordaviprone for use in adult and pediatric patients with H3 K27M-mutated diffuse midline glioma.

New data showed a 72.2% DOR rate in patients with recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer who had a CR at 3 months.

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient quality of life, while emphasizing that temporary treatment holds due to adverse effects are manageable, and ongoing research is vital to address unmet needs and advance multiple myeloma care.

Panelists discuss that the phase 2 TALISMAN trial evaluated prophylactic strategies to prevent severe oral toxicities with talquetamab, highlighting the importance of early patient education, multidisciplinary management, and nutritional support to optimize care and maintain quality of life.

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Cancer survivors, particularly men, in physically demanding jobs often face pressure to keep working during treatment, says Cathy Bradley, PhD.

Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, explained that understanding a patient’s emotional needs can help educate them on treatment adherence.

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in patients with breast cancer.